Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 949 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neuroendocrine Carcinomas Clear all

Conditions: Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
Interventions: E7386, Pembrolizumab, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Orange, California • Fort Myers, Florida + 7 more

Conditions: Adenocarcinoma, Neuroendocrine Tumors, Hepatocellular Carcinoma, Cholangiocarcinoma, Malignant Lymphoma, Metastasis, Chronic Pancreatitis, Autoimmune Pancreatitis
Interventions: EchoTip AcuCore; Device
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Orange, California • Denver, Colorado • Gainesville, Florida + 4 more

Conditions: Advanced Cancer
Interventions: LY3475070, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 7
States / cities: Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more

Conditions: Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Interventions: aNK (NK-92), aNK (NK-92) + N-803; Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)
Interventions: EXS74539; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Fort Worth, Texas • West Valley City, Utah

Conditions: Carcinoid, Neuroendocrine Tumors
Interventions: EPO906 epothilone B; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 5
States / cities: Chicago, Illinois • Iowa City, Iowa • New Orleans, Louisiana + 2 more

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Small Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions: RO7616789, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more

Conditions: Neuroendocrine Tumors, Carcinoma, Neuroendocrine
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions: cediranib maleate, whole-brain radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
Interventions: tanespimycin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Solid Tumors
Interventions: ALKS 4230, ALKS 4230 + pembrolizumab; Drug
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Denver, Colorado • Port Saint Lucie, Florida • Tampa, Florida + 9 more

Conditions: Lung Cancer
Interventions: Stereotactic Body Radiotherapy (SABR); Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Localized Non-Resectable Adult Liver Carcinoma
Interventions: Yttrium-90 Resin Microspheres; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 42
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more

Conditions: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Interventions: Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
Interventions: ADI-PEG 20; Drug
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
Interventions: vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide; Biological · Drug
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Fountain Valley, California • Los Angeles, California • Jacksonville, Florida + 11 more

Conditions: Merkel Cell Carcinoma
Interventions: Pembrolizumab (MK-3475); Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Conditions: Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more

Conditions: Neuroendocrine Carcinoma of Pancreas, Carcinoid
Interventions: Gallium Dotatate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

EchoTip AcuCore Post-Market Clinical Study

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

EPO906 in Carcinoid and Other Neuroendocrine Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers